Inventiva SA
PAR:IVA
Inventiva SA
Additional Paid In Capital
Inventiva SA
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Additional Paid In Capital
€201.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Additional Paid In Capital
€647.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Nanobiotix SA
PAR:NANO
|
Additional Paid In Capital
€312.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Innate Pharma SA
PAR:IPH
|
Additional Paid In Capital
€391m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Additional Paid In Capital
€446.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
17%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Additional Paid In Capital
€20.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-16%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Additional Paid In Capital?
Additional Paid In Capital
201.9m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Additional Paid In Capital amounts to 201.9m EUR.
What is Inventiva SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
7%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Inventiva SA have been 7% over the past three years .
You don't have any saved screeners yet